News
Brentuximab vedotin bests standard of care in CTCL
SAN FRANCISCO—The phase 3 ALCANZA trial is the first to convincingly demonstrate that a new systemic agent can be more effective than standard of...
News
Combos prove no better than 7+3 for AML
SAN DIEGO—Neither a 2-drug combination nor a 3-drug combination is superior to 7+3 chemotherapy in younger patients with previously untreated...
News
Trial supports early treatment of lower-risk ET
Photo courtesy of CDC SAN DIEGO—Results from the ARETA trial suggest patients with essential thrombocythemia (ET) can benefit from early...
News
Study reveals CML patients likely to benefit from HSCT long-term
Photo by Chad McNeeley SAN DIEGO—New research may help inform the management of patients with chronic myeloid leukemia (CML), according to a...
News
Restrictive transfusion strategy should be standard after HSCT, doc says
Photo from UAB Hospital SAN DIEGO—Results of the phase 3 TRIST study support the use of a restrictive red blood cell (RBC) transfusion strategy...
News
Novel interferon appears safer than HU in PV
Photo by Zak Hubbard SAN DIEGO—Results of the PROUD-PV trial suggest ropeginterferon alfa-2b is safer than hydroxyurea (HU) for patients with...
News
Agent exhibits activity in relapsed/refractory AML
acute myeloid leukemia SAN DIEGO—A next-generation DNA hypomethylating agent has demonstrated clinical activity and an acceptable safety profile...
News
Drug produces responses in ‘challenging’ patients
© Todd Buchanan 2016 SAN DIEGO—The oral BCL-2 inhibitor venetoclax can produce high objective response rates (ORRs) in chronic lymphocytic...
News
Rinse could provide short-term treatment of oral cGVHD
Photo courtesy of NIH SAN DIEGO—Results of a phase 2 study suggest an oral mouth rinse formulation of the steroid clobetasol could provide short-...
News
Data suggest one BTK inhibitor could replace another
ASH Annual Meeting SAN DIEGO—When patients with chronic lymphocytic leukemia (CLL) cannot tolerate one Bruton’s tyrosine kinase (BTK) inhibitor,...
News
Obinutuzumab bests rituximab in FL study
ASH Annual Meeting SAN DIEGO—Interim results of the phase 3 GALLIUM trial suggest an obinutuzumab-based treatment regimen provides a progression-...
News
Drug enables transfusion independence in lower-risk MDS
COPENHAGEN—Results from a pair of phase 2 trials suggest luspatercept can produce erythroid responses and enable transfusion independence in...
News
Stopping TKI therapy can be safe, study suggests
COPENHAGEN—Results of a large study suggest that stopping treatment with tyrosine kinase inhibitors (TKIs) can be safe for patients with chronic...
News
Site of major bleeding differs with NOACs and VKAs
COPENHAGEN—Results of a new study suggest that vitamin K antagonists (VKAs) and non-VKA oral anticoagulants (NOACs) can both confer an increased...
News
Platelet transfusion deemed ‘harmful’ in patient group
Congress of the European Hematology Association COPENHAGEN—Results of the phase 3 PATCH trial suggest that platelet transfusions are not...